Enveric Biosciences, Inc.
Enveric Biosciences is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of neuropsychiatric disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. The company focuses on advancing EB-003, a potential first-in-class neuroplastogen designed to promote neuroplasticity without inducing hallucinations, and out-licensing other patented drug candidates. Enveric aims to help millions of patients globally with innovative treatments for mental health conditions.
Industries
Nr. of Employees
small (1-50)
Enveric Biosciences, Inc.
Products
EB-003 (lead neuroplastogen candidate)
Oral small-molecule neuroplastogen candidate designed to promote neuroplasticity without producing hallucinations; being advanced toward clinical development for difficult-to-treat mental health disorders.
EB-002 (synthetic prodrug candidate)
Next-generation synthetic prodrug of an active metabolite being studied as a treatment for psychiatric disorders.
EVM401 series (non-hallucinogenic mescaline-derivative compounds)
Series of non-hallucinogenic derivative compounds intended for indications including addiction and ADHD; reported patent allowances cover this series.
Topical cannabinoid-based formulation (radiation dermatitis product)
Patented topical formulation intended to reduce the side effects of radiation therapy; clinical development and commercialization licensed to a third party.
EB-003 (lead neuroplastogen candidate)
Oral small-molecule neuroplastogen candidate designed to promote neuroplasticity without producing hallucinations; being advanced toward clinical development for difficult-to-treat mental health disorders.
EB-002 (synthetic prodrug candidate)
Next-generation synthetic prodrug of an active metabolite being studied as a treatment for psychiatric disorders.
EVM401 series (non-hallucinogenic mescaline-derivative compounds)
Series of non-hallucinogenic derivative compounds intended for indications including addiction and ADHD; reported patent allowances cover this series.
Topical cannabinoid-based formulation (radiation dermatitis product)
Patented topical formulation intended to reduce the side effects of radiation therapy; clinical development and commercialization licensed to a third party.
Services
Out-licensing and IP licensing
Licensing patented molecules and formulations to third parties under milestone and royalty agreements; supports external clinical development and commercialization by partners.
Preclinical efficacy studies and data generation
Design and execution of preclinical pharmacology studies in animal models to evaluate efficacy and mechanism for candidate small molecules.
Intellectual property strategy and patent prosecution support
Development and management of patent filings and IP assets for small molecules, derivative series, conjugates, and formulations to enable licensing and commercialization.
Strategic partnerships and collaboration facilitation
Establishing and managing collaborations with external companies for clinical development, formulation development, and commercialization of specific assets.
Clinical development planning and regulatory engagement
Preparation for clinical progression of lead candidate(s) including regulatory engagement such as Pre-IND interactions with the FDA.
Out-licensing and IP licensing
Licensing patented molecules and formulations to third parties under milestone and royalty agreements; supports external clinical development and commercialization by partners.
Preclinical efficacy studies and data generation
Design and execution of preclinical pharmacology studies in animal models to evaluate efficacy and mechanism for candidate small molecules.
Intellectual property strategy and patent prosecution support
Development and management of patent filings and IP assets for small molecules, derivative series, conjugates, and formulations to enable licensing and commercialization.
Strategic partnerships and collaboration facilitation
Establishing and managing collaborations with external companies for clinical development, formulation development, and commercialization of specific assets.
Clinical development planning and regulatory engagement
Preparation for clinical progression of lead candidate(s) including regulatory engagement such as Pre-IND interactions with the FDA.
Expertise Areas
- Neuropsychopharmacology
- Small-molecule drug discovery (neuroplastogens)
- Medicinal chemistry and lead optimization
- Preclinical pharmacology and animal models
Key Technologies
- Small-molecule neuroplasticity-focused discovery platform
- Medicinal and synthetic chemistry
- Prodrug design and synthesis
- Cannabinoid-conjugate chemistry